BETHESDA, MD
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)PARENTERAL DRUG ASSOCIATION INC, founded in 1994, is a mid-sized nonprofit that reported $15.3M in total revenue in fiscal year 2024. Revenue grew 13% year-over-year, indicating healthy expansion.
TO DEVELOP SCIENTIFICALLY SOUND, PRACTICAL TECHNICAL INFORMATION AND RESOURCES TO ADVANCE SCIENCE AND REGULATION FOR THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY THROUGH THE EXPERTISE OF OUR GLOBAL MEMBERSHIP.
PROGRAMS & MEETINGS-EDUCATE MEMBERS AND NON-MEMBERS BY TEACHING DEVELOPMENTS IN MANUFACTURING AND QUALITY CONTROL FOR PRIMARY STERILE PRODUCT DEVELOPMENTS.
TRAINING & RESEARCH INSTITUE (TRI)EDUCATIONAL COURSES - TECHNICAL TRAINING FOR SCIENTISTS IN THE PHARMACEUTICAL AREAS OF MANUFACTURING, DEVELOPMENT AND QUALITY CONTROL. TRAINING - TRAIN MEMBERS AND...
TRAINING & RESEARCH INSTITUE (TRI)EDUCATIONAL COURSES - TECHNICAL TRAINING FOR SCIENTISTS IN THE PHARMACEUTICAL AREAS OF MANUFACTURING, DEVELOPMENT AND QUALITY CONTROL. TRAINING - TRAIN MEMBERS AND NON-MEMBERS TO BASIC MANUFACTURING TECHNIQUES CENTERED AROUND GMP GUIDELINES.
MEMBERSHIP & CHAPTER SERVICES-PROVIDE THE LATEST GUIDELINES FOCUSING ON TECHNOLOGY INFORMATION ON MANUFACTURING, TECHNICAL REPORTS, AND QUALITY CONTROL.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $15,336,776 | $13,567,833 | +0.1% |
| Expenses | $15,667,738 | $13,508,016 | +0.2% |
| Net Income | $-330,962 | $59,817 | -6.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ANIL SAWANT PHD | CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| MELISSA SEYMOUR MBA | CHAIR-ELLECT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| SUSAN SCHNIEPP | IMMEDIATE PAST CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| EMMA RAMNARINE | TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| BETTINE BOLTRES PHD | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| LISA BENNETT | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CHRISTIANA CAMPA | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ANDREW CHANG | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CYLIA CHEN QOI | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MIRKO GABRIELE | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MARC GLOGOVSKY | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ANDREW HOPKINS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| STEPHAN KRAUSE PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| IVY LOUIS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| AMY MCDANIEL | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| BRIGITTE REUTTER-HAERLE | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| OSAMU SKIROKIZAWA | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| GLENN WRIGHT | CEO | 37.50 |
Officer
|
$426,542 | $46,970 | $473,512 |
| JENNIFER BELL | CFO | 37.50 |
Key Emp
|
$239,928 | $53,529 | $293,457 |
| DAVID HALL | VP EXHIBITS | 37.50 |
Key Emp
|
$243,228 | $66,092 | $309,320 |
| DAVID TALMAGE | VP EDUCATION | 37.50 |
Key Emp
|
$217,711 | $72,104 | $289,815 |
| MOLLY O'NEILL | VP PROGRAMS | 37.50 |
Key Emp
|
$216,974 | $61,179 | $278,153 |
| WALTER MORRIS III | SR DIRECTOR PUBLICATIONS | 37.50 |
Highest
|
$174,796 | $35,212 | $210,008 |
| ALETHEA TAVARES | CHIEF OF STAFF | 37.50 |
Highest
|
$162,887 | $27,694 | $190,581 |
| JOSHUA EATON | SR DIRECTOR SRA | 37.50 |
Highest
|
$161,218 | $38,848 | $200,066 |
| MICHAEL PORTER | SR DIRECTOR, EDUCATION | 37.50 |
Highest
|
$140,141 | $16,817 | $156,958 |
| FARAMARZ KOLIVAND | SR WEB DEVELOPER | 37.50 |
Highest
|
$143,243 | $34,298 | $177,541 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $15,336,776 | $15,667,738 | $18,736,014 | $-330,962 |
| 2022 | $15,089,728 | $13,301,962 | $20,602,292 | $1,787,766 |
| 2021 | $8,044,773 | $10,547,266 | $14,078,226 | $-2,502,493 |
| 2020 | $7,747,423 | $9,503,016 | $13,130,551 | $-1,755,593 |
| 2019 | $12,218,515 | $14,012,166 | $13,763,882 | $-1,793,651 |
| 2018 | $14,350,028 | $13,527,896 | $14,031,792 | $822,132 |
Compare PARENTERAL DRUG ASSOCIATION INC with other nonprofits in Maryland and across the country.